Development of an Inhaled Dry-Powder Formulation of Tobramycin Using PulmoSphere™ Technology
- 1 August 2011
- journal article
- review article
- Published by Mary Ann Liebert Inc in Journal of Aerosol Medicine and Pulmonary Drug Delivery
- Vol. 24 (4), 175-182
- https://doi.org/10.1089/jamp.2010.0855
Abstract
At present, the only approved inhaled antipseudomonal antibiotics for chronic pulmonary infections in patients with cystic fibrosis (CF) are nebulized solutions. However, prolonged administration and cleaning times, high administration frequency, and cumbersome delivery technologies with nebulizers add to the high treatment burden in this patient population. PulmoSphere™ technology is an emulsion-based spray-drying process that enables the production of light porous particle, dry-powder formulations, which exhibit improved flow and dispersion from passive dry powder inhalers. This review explores the fundamental characteristics of PulmoSphere technology, focusing on the development of a dry powder formulation of tobramycin for the treatment of chronic pulmonary Pseudomonas aeruginosa (Pa) infection in CF patients. This dry powder formulation provides substantially improved intrapulmonary deposition efficiency, faster delivery, and more convenient administration over nebulized formulations. The availability of more efficient and convenient treatment options may improve treatment compliance, and thereby therapeutic outcomes in CF.Keywords
This publication has 27 references indexed in Scilit:
- Pulmonary Formulations: What Remains to be Done?Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2010
- Infection control in cystic fibrosis: barriers to implementation and ideas for improvementCurrent Opinion in Pulmonary Medicine, 2009
- Efficacy and Safety of Inhaled Aztreonam Lysine for Airway Pseudomonas in Cystic FibrosisChest, 2009
- High treatment burden in adults with cystic fibrosis: Challenges to disease self-managementJournal of Cystic Fibrosis, 2009
- The science of aerosol delivery in cystic fibrosisPediatric Pulmonology, 2008
- Design of fine particles for pulmonary drug deliveryExpert Opinion on Drug Delivery, 2007
- Novel tobramycin inhalation powder in cystic fibrosis subjects: Pharmacokinetics and safetyPediatric Pulmonology, 2007
- Effect of Dry Powder Inhaler Resistance on the Inspiratory Flow Rates and Volumes of Cystic Fibrosis Patients of Six Years and OlderJournal of Aerosol Medicine, 2006
- Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosisPediatric Pulmonology, 2002
- Inhaled micronised gentamicin powder: a new delivery system.Thorax, 1990